RAPT Therapeutics, Inc. (RAPT)

Kritische 8-K Meldungen

Datum	Meldung	Schwere	Filing	Auszug
28.11.2025	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment
23.06.2025	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment
29.05.2025	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment
27.03.2025	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of
06.01.2025	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of
15.11.2024	Item 5.02 — Abgang Schlüsselpersonen	HOCH	SEC	(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of

Stammdaten

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Unternehmen & Branche

Name	RAPT Therapeutics, Inc.
Ticker	RAPT
CIK	0001673772
Sektor	Healthcare
Industrie	Biotechnology
SIC	2834 · Pharmaceutical Preparations

Wertpapier & Kennzahlen

CUSIP	–
ISIN	–
Typ	–
Marktkapitalisierung	959,3 Mio. USD
Beta	0,44
Dividendenrendite	0,00 %

Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »

Finanzkennzahlen (SEC XBRL)

Periode	Filing	Umsatz	Nettoergebnis	EPS	Aktiva	Eigenkapital
2025-09-30	10-Q		-17,580,000	-0.65	165,739,000	151,977,000
2025-06-30	10-Q		-17,643,000	-0.65	178,410,000	164,408,000
2025-03-31	10-Q		-17,165,000	-0.08	187,570,000	177,372,000
2024-12-31	10-K		-129,865,000	-3.19	240,325,000	189,904,000
2024-09-30	10-Q		-18,432,000	-3.79	108,465,000	95,506,000
2024-06-30	10-Q		-27,663,000	-5.69	127,180,000	109,220,000
2024-03-31	10-Q		-30,521,000	-0.79	155,818,000	130,835,000
2023-12-31	10-K	0	-116,798,000	-3.05	173,329,000	147,035,000
2023-09-30	10-Q	0	-31,371,000	-0.82	199,721,000	172,800,000
2023-06-30	10-Q	0	-25,280,000	-0.66	220,756,000	199,677,000
2023-03-31	10-Q		-29,271,000	-0.76	248,326,000	220,470,000
2022-12-31	10-K	1,527,000	-83,838,000	-2.58	266,209,000	245,166,000
2022-09-30	10-Q	0	-21,235,000	-0.63	209,489,000	189,306,000
2022-06-30	10-Q	886,000	-19,184,000	-0.62	221,996,000	202,133,000
2022-03-31	10-Q	641,000	-20,468,000	-0.69	187,548,000	167,835,000
2021-12-31	10-K	3,813,000	-69,204,000	-2.53	198,636,000	186,380,000
2021-09-30	10-Q	966,000	-18,651,000	-0.63	217,462,000	201,873,000
2021-06-30	10-Q	869,000	-16,110,000	-0.63	231,081,000	217,579,000
2021-03-31	10-Q	1,222,000	-16,514,000		105,924,000	91,641,000
2020-12-31	10-K	5,042,000	-52,892,000		118,969,000	104,179,000

Fondsaktivität (Vorquartalsvergleich)

Keine Fondsdaten für dieses Unternehmen vorhanden.

Insider-Transaktionen (12 Monate)

Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.

Top-Fondshalter

Keine Fondsdaten zu dieser Aktie vorhanden.